Wednesday, 16 May 2012 | Source: Reuters
(Reuters) - Array BioPharma Inc's experimental lung cancer drug, selumetinib, w as shown to increase survival by an additional 4.2 months over chemotherapy alone, according to new data released on Wednesday.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Wednesday, 9 May 2012 | Source: Reuters
LONDON (Reuters) - GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board.
Monday, 7 May 2012 | Source: Reuters
NEW YORK (Reuters) - More than 100 years after researchers first explored the potential to harness the body's immune system to fight cancer, the field's leading doctors see the concept finally proving itself on a large scale in the next year or two.
Thursday, 3 May 2012 | Source: Reuters
CHICAGO/WASHINGTON (Reuters) - The U.S. government will help drug companies find treatments for a host of diseases through a new collaboration in which researchers will test experimental drugs provided by manufacturers.
Posts |
COMPANY : ASTRAZENECA PLC
30 Apr 2012
Posted By:ReutersCNBC Stock Blog Europe
AstraZeneca may be lacking both drugs and a CEO, but for brave investors this might be the time to buy the stock... Read More
20 Mar 2012
Take a look at some of Tuesday morning’s early movers:... Read More
14 Mar 2012
Posted By:Adam Feuerstein CNBC Stock Blog
Savvy investors know that making money on the “ASCO trade” means getting in early as cancer drug stocks typically trade up into the closely watched medical meeting... Read More
9 Mar 2012
Take a look at some of Friday morning's early movers:... Read More
29 Feb 2012
Posted By:David ReidCNBC Stock Blog Europe
Information technology and healthcare are two sectors where investors can find value, Peter Garnry, equity strategist at Saxo Bank told CNBC.... Read More
VIDEO | COMPANIES : ASTRAZENECA PLC
Cramer shares six stocks to watch in less than 60 seconds, including upgrades for Gap and Qualcomm, and Oppenheimer come...
Warren East, CEO of ARM Holdings, a company which designs chips used in smartphones, says he is not worried about compet...
Mad Money host Jim Cramer explains why he'd rather buy Eaton Corporation or Cooper Industries over an over-hyped media c...
David Kotok, Chairman & CIO, Cumberland Advisors says the European Central Bank is the only game in town when it comes t...
Barclays is selling its $6.1 billion stake in BlackRock, with plans to use the cash to help boost its profitability and ...
More Videos
Data is a real-time snapshot *Data is delayed at least 15 minutesGlobal Business and Financial News, Stock Quotes, and Market Data and Analysis
© 2012 CNBC LLC. All Rights Reserved.
